Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
21.91
+0.32
+(1.48%)
At close: April 11 at 4:00:01 PM EDT
21.91
-0.00
(-0.00%)
After hours: April 11 at 7:59:58 PM EDT
Loading Chart for PFE
  • Previous Close 21.59
  • Open 21.59
  • Bid 21.85 x 1000
  • Ask 21.92 x 3000
  • Day's Range 21.28 - 21.98
  • 52 Week Range 20.92 - 31.54
  • Volume 45,199,720
  • Avg. Volume 49,489,493
  • Market Cap (intraday) 124.261B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) 15.54
  • EPS (TTM) 1.41
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield 1.72 (7.49%)
  • Ex-Dividend Date Jan 24, 2025
  • 1y Target Est 30.54

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

81,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

View More

Performance Overview: PFE

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PFE
16.05%
S&P 500 (^GSPC)
8.81%

1-Year Return

PFE
11.60%
S&P 500 (^GSPC)
3.16%

3-Year Return

PFE
53.06%
S&P 500 (^GSPC)
21.55%

5-Year Return

PFE
18.66%
S&P 500 (^GSPC)
92.25%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

View More

Valuation Measures

As of 4/11/2025
  • Market Cap

    124.26B

  • Enterprise Value

    167.43B

  • Trailing P/E

    15.54

  • Forward P/E

    7.45

  • PEG Ratio (5yr expected)

    0.52

  • Price/Sales (ttm)

    1.96

  • Price/Book (mrq)

    1.41

  • Enterprise Value/Revenue

    2.63

  • Enterprise Value/EBITDA

    9.24

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.62%

  • Return on Assets (ttm)

    4.64%

  • Return on Equity (ttm)

    9.06%

  • Revenue (ttm)

    63.63B

  • Net Income Avi to Common (ttm)

    8.02B

  • Diluted EPS (ttm)

    1.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.48B

  • Total Debt/Equity (mrq)

    76.18%

  • Levered Free Cash Flow (ttm)

    12.78B

Research Analysis: PFE

View More

People Also Watch